6.
Wallace J, Macnaughton W, Morris G, Beck P
. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology. 1989; 96(1):29-36.
DOI: 10.1016/0016-5085(89)90760-9.
View
7.
Forman B, Chen J, Evans R
. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997; 94(9):4312-7.
PMC: 20719.
DOI: 10.1073/pnas.94.9.4312.
View
8.
Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters J, Gonzalez F
. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem. 1999; 274(45):32048-54.
DOI: 10.1074/jbc.274.45.32048.
View
9.
Na Y, Jung D, Stakenborg M, Jang H, Gu G, Jeong M
. Prostaglandin E receptor PTGER4-expressing macrophages promote intestinal epithelial barrier regeneration upon inflammation. Gut. 2021; 70(12):2249-2260.
DOI: 10.1136/gutjnl-2020-322146.
View
10.
Ghosh S, May M, Kopp E
. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998; 16:225-60.
DOI: 10.1146/annurev.immunol.16.1.225.
View
11.
Morris G, Beck P, Herridge M, Depew W, Szewczuk M, Wallace J
. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989; 96(3):795-803.
View
12.
Ajuebor M, Singh A, Wallace J
. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2000; 279(1):G238-44.
DOI: 10.1152/ajpgi.2000.279.1.G238.
View
13.
Wallace J, Devchand P
. Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense. Br J Pharmacol. 2005; 145(3):275-82.
PMC: 1576151.
DOI: 10.1038/sj.bjp.0706201.
View
14.
Glas J, Seiderer J, Czamara D, Pasciuto G, Diegelmann J, Wetzke M
. PTGER4 expression-modulating polymorphisms in the 5p13.1 region predispose to Crohn's disease and affect NF-κB and XBP1 binding sites. PLoS One. 2013; 7(12):e52873.
PMC: 3531335.
DOI: 10.1371/journal.pone.0052873.
View
15.
Liang P, Pardee A
. Analysing differential gene expression in cancer. Nat Rev Cancer. 2003; 3(11):869-76.
DOI: 10.1038/nrc1214.
View
16.
Krey G, Braissant O, LHorset F, Kalkhoven E, Perroud M, Parker M
. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997; 11(6):779-91.
DOI: 10.1210/mend.11.6.0007.
View
17.
Argmann C, Hou R, Ungaro R, Irizar H, Al-Taie Z, Huang R
. Biopsy and blood-based molecular biomarker of inflammation in IBD. Gut. 2022; 72(7):1271-1287.
PMC: 10014487.
DOI: 10.1136/gutjnl-2021-326451.
View
18.
Drew D, Kim A, Lin Y, Qu C, Morrison J, Lewinger J
. Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer. Sci Adv. 2024; 10(22):eadk3121.
PMC: 11135391.
DOI: 10.1126/sciadv.adk3121.
View
19.
Funk C
. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294(5548):1871-5.
DOI: 10.1126/science.294.5548.1871.
View
20.
Zamuner S, Bak A, Devchand P, Wallace J
. Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol. 2005; 167(5):1293-300.
PMC: 1603786.
DOI: 10.1016/S0002-9440(10)61216-3.
View